 |
11 Diseases |  |
38 Trials |
|
38 Trials |  |
2772 News |  |
| «12...2223242526272829303132...3839» |
- Tremfya (guselkumab) / J&J
[VIRTUAL] Improvement in Absolute Psoriasis Area and Severity Index Through 5 Years of Continuous Treatment with Guselkumab in the VOYAGE 1 Trial () - Jul 15, 2021 - Abstract #IFPA2021IFPA_210;
Continuous treatment with GUS was well tolerated and provided robust and durable skin responses based on absolute PASI through 5 years.
- || Humira (adalimumab) / Eisai, AbbVie, Tremfya (guselkumab) / J&J
Clinical, Journal: Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2. (Pubmed Central) - Jul 14, 2021
P3
In both populations, DLQI 0/1 responses were greater in guselkumab-treated versus placebo- and adalimumab-treated patients at week 16 and versus adalimumab-treated patients at week 24. Guselkumab safety and efficacy were consistent between Hispanic and non-Hispanic populations.
- || Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Review, Journal: Review of treatments for generalized pustular psoriasis manuscript. (Pubmed Central) - Jul 14, 2021
Several medications targeting IL-17 or IL-23 have also emerged recently with drugs such as ixekizumab, secukinumab, brodalumab, guselkumab and ustekinumab having shown some efficacy. This review highlights the research in support of common treatments of GPP, including classically used medications and newer monoclonal antibodies, and addresses the continued need for high quality studies regarding treatments for this condition.
- || Review, Journal: Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. (Pubmed Central) - Jul 14, 2021
Selective interleukin-23 inhibitors require less frequent dosing than interleukin-17 inhibitors and may possess a more favorable risk profile without an increased risk of candidiasis or inflammatory bowel disease. Overall, these highly effective medications are contributing to a rising standard for psoriasis outcomes through resolution of skin lesions and joint manifestations and improvement of patient quality of life.
- || Review, Journal: Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules. (Pubmed Central) - Jul 10, 2021
Additional molecules are in an early phase of development. Highly promising biologicals and small oral molecules are the leading edge of the systemic treatment of psoriasis.
- ||||| Tremfya (guselkumab) / J&J
Clinical: #ECCO2021 @silvio_silvio75 with the data on GUselkumab data from GALAXI 1 study in #CD ⏺Impressive early (wk 4!) remission which progressively increase to wk 12 ⏺ concerns regarding power 🤔 (Twitter) - Jul 9, 2021
- ||||| Tremfya (guselkumab) / J&J
Great induction results of GUSELKUMAB by @silvio_silvio75 in CD #ECCO2021 IL-23 are coming! (Twitter) - Jul 9, 2021
- ||| Tremfya (guselkumab) / J&J
Enrollment open: A Study of Guselkumab in Adult Participants With Celiac Disease (clinicaltrials.gov) - Jul 8, 2021
P1b, N=70, Recruiting, Sponsor: Janssen Research & Development, LLC
Highly promising biologicals and small oral molecules are the leading edge of the systemic treatment of psoriasis. Not yet recruiting --> Recruiting
- ||| Tremfya (guselkumab) / J&J
Trial completion date: GALAXI: A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Jul 7, 2021
P2/3, N=2000, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Trial completion date: Feb 2025 --> Nov 2024
- | Tremfya (guselkumab) / J&J
Trial completion date: A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants (clinicaltrials.gov) - Jul 7, 2021
P1, N=568, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Feb 2025 --> Nov 2024 Trial completion date: Sep 2021 --> Dec 2021
- | Tremfya (guselkumab) / J&J
Trial completion date: A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Jul 7, 2021
P3, N=25, Recruiting, Sponsor: Janssen Pharmaceutical K.K.
Trial completion date: Sep 2021 --> Dec 2021 Trial completion date: Sep 2024 --> Feb 2025
- Humira (adalimumab) / Eisai, AbbVie, Tremfya (guselkumab) / J&J
[VIRTUAL] Real-world effectiveness of guselkumab in achieving absolute PASI thresholds and mean DLQI scores in patients with moderate-to-severe plaque psoriasis: analysis of the BADBIR registry following 6 months of treatment () - Jul 5, 2021 - Abstract #BAD2021BAD_601;
These data were representative of bio-naïve and bio-experienced patients’ achievement of aPASI ≤ 3 and aPASI ≤ 5; however, more bio-naïve patients achieved aPASI ≤ 1. A reduced impact of psoriatic disease on the quality of life of patients may be conferred by the higher clinical effects of guselkumab on aPASI.
- Tremfya (guselkumab) / J&J
[VIRTUAL] Using Tremfya® (guselkumab), the latest biologic licensed for both psoriasis and psoriatic arthritis1 : a case-based discussion from a combined clinic () - Jul 5, 2021 - Abstract #BAD2021BAD_459;
A reduced impact of psoriatic disease on the quality of life of patients may be conferred by the higher clinical effects of guselkumab on aPASI. Sponsored Symposium: Janssen
- Tremfya (guselkumab) / J&J
[VIRTUAL] Combined dermatology–rheumatology clinics: what are the benefits for me and my patients? () - Jul 5, 2021 - Abstract #BAD2021BAD_455;
This is a promotional symposium organised and funded by Janssen and is intended for UK healthcare professionals only. Tremfya® (guselkumab) prescribing information is available at www.janssen-pi.co.uk/tremfya and adverse events reporting information can be found below
- | Humira (adalimumab) / Eisai, AbbVie
Journal: HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis. (Pubmed Central) - Jul 4, 2021
Rituximab achieved a good control of psoriasis. Unfortunately, the patient developed Staphylococcus aureus sepsis for which he is currently on antibiotic therapy.
- ||| Tremfya (guselkumab) / J&J
Enrollment change: A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Jul 3, 2021
P4, N=300, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
Unfortunately, the patient developed Staphylococcus aureus sepsis for which he is currently on antibiotic therapy. N=150 --> 300
- || Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Tremfya (guselkumab) / J&J
Clinical, Journal, Head-to-Head: A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial. (Pubmed Central) - Jul 3, 2021
P4
Ixekizumab cleared skin more rapidly in patients with moderate-to-severe plaque psoriasis, with a greater cumulative benefit, than guselkumab. Overall, safety findings were consistent with the known safety profile for ixekizumab.
- || Enbrel (etanercept) / Pfizer, Amgen
Review, Journal: Interventions for chronic palmoplantar pustulosis: abridged Cochrane systematic review and GRADE assessments. (Pubmed Central) - Jul 3, 2021
Evidence is lacking for or against major chronic PPP treatments. Risk of bias and imprecision limit our confidence in the results.
- || Tremfya (guselkumab) / J&J
Clinical, Journal, Real-world evidence: Real-world effectiveness and safety of Guselkumab for the treatment of psoriasis: a 6-month prospective study in a series of psoriatic patients. (Pubmed Central) - Jul 2, 2021
Risk of bias and imprecision limit our confidence in the results. This study demonstrates the effectiveness and safety of Guselkumab on PSO in real world and shows that the reduction of PSO severity due to the drug is directly related with the improvement of quality of life in this patient population.
- | Tremfya (guselkumab) / J&J
Journal: Guselkumab in the Treatment of Severe Hidradenitis Suppurativa, a Promising Role? (Pubmed Central) - Jul 2, 2021
This study demonstrates the effectiveness and safety of Guselkumab on PSO in real world and shows that the reduction of PSO severity due to the drug is directly related with the improvement of quality of life in this patient population. No abstract available
- || Review, Journal: The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges. (Pubmed Central) - Jul 2, 2021
To date, no clinical studies targeting IL17 pathway are ongoing in UC. IL-17 targeting is thought to have a context-dependent biological effect, based on whether cytokine is selectively targeted or if its function is dampened by the upstream block of IL23.
- || Tremfya (guselkumab) / J&J
Review, Journal: Guselkumab for the Treatment of Palmoplantar Pustulosis: A Japanese Perspective. (Pubmed Central) - Jul 1, 2021
Such cases are considered to be indications of biologics. In this review, clinical features, pathophysiology and guselkumab therapy are discussed.
- |||||| Tremfya (guselkumab) / J&J
New trial: Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis (clinicaltrials.gov) - Jul 1, 2021
P, N=0, Available, Sponsor: Janssen Research & Development, LLC
- || Tremfya (guselkumab) / J&J
Retrospective data, Review, Journal, HEOR: Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. (Pubmed Central) - Jul 1, 2021
In this review, clinical features, pathophysiology and guselkumab therapy are discussed. In this NMA, guselkumab demonstrated favorable arthritis efficacy comparable to IL-17A and subcutaneous TNF inhibitors while offering better PASI response relative to many other treatments.
- || Retrospective data, Review, Journal: Meta-analysis and Indirect Comparisons: On Methods, Paradigms, and Biologic Treatments for Psoriasis. (Pubmed Central) - Jun 26, 2021
According to NMA findings, the 4 most effective treatments in both the short term (10-16 weeks) and the long term (approximately 1 year) are, in rank order, risankizumab (first in all studies that include it), brodalumab, guselkumab, and ixekizumab. However, the between-treatment differences were not always significant.
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Tremfya (guselkumab) / J&J
[VIRTUAL] Ixekizumab Provides More Durable Improvements in Skin Clearance, Itch, and Quality of Life than Guselkumab in Patients with Moderate-to-Severe Psoriasis: 24-week Results from IXORA-A () - Jun 23, 2021 - Abstract #SDDS2021SDDS_102;
- Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] IL-17 inhibitors and IL-23 inhibitors () - Jun 23, 2021 - Abstract #SDDS2021SDDS_26;
Tildrakizumab showed retention of efficacy from the 5-year pooled data from reSURFACE 1 and reSURFACE 2...In the IMMerge trial, risankizumab was shown to have higher PASI 100 responses than secukinumab at weeks 52. In the BE RADIANT trial, bimekizumab was shown to have higher PASI 90 responses than secukinumab at weeks 16 and 48.
- |||||||||| Tremfya (guselkumab) / J&J
New P3 trial: SOLSTICE: Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent (clinicaltrials.gov) - Jun 23, 2021
P3b, N=450, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- || Tremfya (guselkumab) / J&J
Clinical, Journal: Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis. (Pubmed Central) - Jun 22, 2021
Using MA-GUS12A9 as a calibrator, two anti-guselkumab antibody assays were developed to detect anti-guselkumab antibodies, which differ in the threshold for detection and quantification and the tolerance to the presence of guselkumab. Together, these validated immunoassays are essential to establish a concentration-response relationship and will allow the future implementation of therapeutic drug monitoring in moderate-to-severe psoriasis patients receiving guselkumab treatment.
- | Tremfya (guselkumab) / J&J
Journal: Treatment of recalcitrant subcorneal pustular dermatosis with guselkumab. (Pubmed Central) - Jun 22, 2021
Together, these validated immunoassays are essential to establish a concentration-response relationship and will allow the future implementation of therapeutic drug monitoring in moderate-to-severe psoriasis patients receiving guselkumab treatment. No abstract available
- | Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
Retrospective data, Journal: Relative efficacy and safety of secukinumab and guselkumab for the treatment of active psoriatic arthritis: A network meta-analysis. (Pubmed Central) - Jun 22, 2021
Based on the ACR20 and ACR50 response rates, secukinumab 300 mg had the strongest response effectiveness, whereas guselkumab 100 mg Q4W was the most effective treatment strategy for PsA based on PASI75. However, there was little disparity between the treatment options with regard to SAEs.
- ||||| Tremfya (guselkumab) / J&J
New P4 trial: STAR: A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease (clinicaltrials.gov) - Jun 18, 2021
P4, N=405, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- |||| Tremfya (guselkumab) / J&J
Clinical: Patient with #ESKD and #psoriasis seen by Dermatology and wants to start #guselkumab (Tremfya). Any safety data in patients with impaired kidney function? #DermTwitter #NephTwitter (Twitter) - Jun 17, 2021
- ||| Humira (adalimumab) / Eisai, AbbVie, Tremfya (guselkumab) / J&J
Clinical, P3 data, Journal: Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. (Pubmed Central) - Jun 16, 2021
P3
High efficacy levels were maintained from week 100 through to week 204 with continuous guselkumab treatment, across multiple endpoints, in VOYAGE 2. Guselkumab was well tolerated.
- ||| Tremfya (guselkumab) / J&J
Biomarker, Enrollment open, Trial completion date, Trial primary completion date: An Explorative Psoriasis Biomarker Study (clinicaltrials.gov) - Jun 14, 2021
P=N/A, N=50, Recruiting, Sponsor: Centre for Human Drug Research, Netherlands
Guselkumab was well tolerated. Not yet recruiting --> Recruiting | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Oct 2021 --> Oct 2022
- || Tremfya (guselkumab) / J&J
Clinical, P2 data, Journal: Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study. (Pubmed Central) - Jun 11, 2021
P2a
At week 24, the guselkumab group had greater mean improvements in enthesitis and dactylitis and greater proportions of patients with resolution of enthesitis and dactylitis versus placebo. ACR20 response was associated with improvements in enthesitis and dactylitis.
- || Tremfya (guselkumab) / J&J
Clinical, Journal, Real-world evidence: Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period. (Pubmed Central) - Jun 10, 2021
Adverse events were experienced by five patients (7.4%), and all were mild in severity. In this first real-world study on guselkumab among Chinese patients with psoriasis, this biologics was shown to be safe and effective in reaching an optimal clinical response up to 20 weeks.
- || Tremfya (guselkumab) / J&J
Trial completion date: QUASAR: A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Jun 9, 2021
P2b, N=950, Recruiting, Sponsor: Janssen Research & Development, LLC
In this first real-world study on guselkumab among Chinese patients with psoriasis, this biologics was shown to be safe and effective in reaching an optimal clinical response up to 20 weeks. Trial completion date: Jul 2025 --> Dec 2025
- |||||| Tremfya (guselkumab) / J&J
Enrollment open, Trial completion date: APEX: A Study of Guselkumab in Participants With Active Psoriatic Arthritis (clinicaltrials.gov) - Jun 9, 2021
P3b, N=950, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Jul 2025 --> Dec 2025 Not yet recruiting --> Recruiting | Trial completion date: Nov 2026 --> Jun 2026
- | Tremfya (guselkumab) / J&J
Artrite psoriasica, buoni risultati per guselkumab #EULAR2021 https://t.co/7CIzualwbw (Twitter) - Jun 8, 2021
- Tremfya (guselkumab) / J&J
[VIRTUAL] Guselkumab Treatment Modulates Core Psoriatic Arthritis Gene Expression in Two Phase 3 Clinical Trials (DISCOVER-1 and -2) (Room 4) - Jun 7, 2021 - Abstract #EULAR2021EULAR_4659;
- | Humira (adalimumab) / Eisai, AbbVie, Tremfya (guselkumab) / J&J
Retrospective data, Journal: Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) - Jun 5, 2021
The guselkumab was more effective and had the similar tolerance. The guselkumab had excellent efficacy and great safety in moderate-to-severe plaque psoriasis, but long-term safety remained to be determined.
- |||| Tremfya (guselkumab) / J&J
DISCOVER 1&2: whole blood transcriptome in PsA: dysregulation of immune cell profiles vs. Ctrl Guselkumab modulates genes expr towards normalization of immune cell composition. Would be interesting to look at STissue signatures too 🧐 @StefanSiebert1 #POS0195 @Rheumnow #EULAR2021 (Twitter) - Jun 4, 2021
- ||||| Tremfya (guselkumab) / J&J
Clinical: COSMOS study: Guselkumab RCT in PsA pts TNFi-resistants (1 or 2) 44.4% of GUS vs 19.8% of PBO pts achieved ACR20 at w24 (p<0.001) and GUS > PBO for most secondary endpoints. Tolerance: 18% vs. 20% infections/SI. #OP0230 @Rheumnow #EULAR2021 @DrLauraCoates (Twitter) - Jun 4, 2021
- |||||| Tremfya (guselkumab) / J&J
Clinical, P3 data: Novel target (IL23-i; Guselkumab) in treating TNF-IR #psoriaticarthritis. Dr Coates presented results from Phase III COSMOS. 44.4% of GUS-treated vs 19.8% Placebo-tx achieved ACR20 response at Wk24 (p<0.001). Well tolerated and No major safety #EULAR2021 #OP0230 @RheumNow (Twitter) - Jun 4, 2021
- |||| Tremfya (guselkumab) / J&J
New P4 trial: A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Jun 3, 2021
P4, N=150, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- || Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim, Tremfya (guselkumab) / J&J
Clinical, Journal: Efficacy of in-class IL-23 inhibitor switching: Risankizumab following Guselkumab failure in moderate-to-severe psoriasis treatment. (Pubmed Central) - Jun 3, 2021
IL-23 inhibitors in particular, including guselkumab and risankizumab have been shown to be highly effective and have a favorable safety profile. Though recent studies have shown that in-class biologic switching can be effective in the treatment of psoriasis, no investigation has assessed the efficacy of an in-class IL-23 inhibitor switch..
- || Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Epidemiological survey of the psoriasis patients in the Japanese Society for Psoriasis Research from 2013 to 2018. (Pubmed Central) - Jun 3, 2021
In the past decade, the biologics have changed the treatment and management of psoriasis. This survey includes significant information regarding the recent perspective of psoriasis in the Japanese Society, especially focusing on the treatment trends after the introduction of biologics.
- || Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis, Otezla (apremilast) / Amgen
Clinical, Journal: Additional effect of excimer light therapy in patients with psoriasis under other therapies. (Pubmed Central) - Jun 3, 2021
Other therapies were composed of apremilast and biologics...In addition, irradiation amount in patients reached PASI-100 in Guselkumab (717 ± 75 mJ) which was significantly smaller that in the excimer only group (1530 ± 450 mJ). Additional effect of excimer light therapy in psoriasis, especially in patients with guselkumab, was speculated.
- || Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
Cosentyx binds to interleukin-17A (IL-17A) whereas Tremfya blocks the activity of interleukin 23 (IL-23). For more detailed information please see our website: https://t.co/y4mXJL7WiK (2) (Twitter) - Jun 2, 2021